A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil
Katsumasa Kuroi, Tetsuya Toge(Hiroshima University), Shigeru Murakami(Fukui Prefectural University), Hiroyuki Kawami, Akihiko Osaki(Hiroshima University)
Cited by 1
Related Papers
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
|Cancer Chemotherapy and Pharmacology|2002|255
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|122
Targeted therapy against Bcl-2-related proteins in breast cancer cells
|Breast Cancer Research|2005|114
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
|International Journal of Cancer|1992|111